Mirtazapine

Generic Name: Mirtazapine

Brand Names: Remeron

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉N_₃

CAS Number: 85650-52-8

Unique Ingredient Identifier: A051Q2099Q

Background: Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early ...

Indication: This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
...

Associated Conditions: Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache

Associated Therapies: -

Clinical Trials

Novel Pilot Study to Treat Symptoms of IBS with Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator

Early Phase 1

Not yet recruiting

Conditions: IBS - Irritable Bowel Syndrome
Diarrhea

Interventions: Drug: Mirtazapine
Other: Placebo

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-12

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT06684470

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

Phase 2

Recruiting

Conditions: Stimulant Use Disorder

Interventions: Drug: Placebo
Drug: Mirtazapine

First Posted Date: 2024-03-21

Last Posted Date: 2024-08-13

Lead Sponsor: Washington State University

Target Recruit Count: 60

Registration Number: NCT06323837

Locations: 🇺🇸
Spokane Treatment Center, Spokane, Washington, United States

Trial of Mirtazapine for Depression in IBD

Phase 2

Recruiting

Conditions: Major Depressive Disorder
Inflammatory Bowel Diseases

Interventions: Drug: Placebo
Drug: Mirtazapine

First Posted Date: 2024-03-13

Last Posted Date: 2024-08-22

Lead Sponsor: King's College London

Target Recruit Count: 76

Registration Number: NCT06309472

Locations: 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
St Mark's Hospital, London, United Kingdom

and more 1 locations

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

Phase 1

Withdrawn

Conditions: Pregnancy
Severe Nausea and Vomiting
Hyperemesis Gravidarum

Interventions: Drug: Mirtazapine

First Posted Date: 2022-07-11

Last Posted Date: 2024-12-11

Lead Sponsor: Northwestern University

Target Recruit Count: 2

Registration Number: NCT05452174

Locations: 🇺🇸
Northwestern University Asher Center for the Study and Treatment of Depressive Disorders, Chicago, Illinois, United States

Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.

Phase 2

Conditions: Anorexia

Interventions: Drug: Megestrol Acetate
Drug: Mirtazapine

First Posted Date: 2022-05-18

Last Posted Date: 2022-05-18

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 80

Registration Number: NCT05380479

Locations: 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer

Phase 2

Conditions: Anorexia Nervosa with Significantly Low Body Weight

Interventions: Drug: Mirtazapine
Drug: Olanzapine

First Posted Date: 2021-12-28

Last Posted Date: 2022-07-26

Lead Sponsor: Englewood Hospital and Medical Center

Target Recruit Count: 170

Registration Number: NCT05170919

Locations: 🇺🇸
Englewood Health, Englewood, New Jersey, United States

Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache

Phase 4

Completed

Conditions: Headache

Interventions: Drug: Mirtazapine
Drug: Sumatriptan
Other: Placebo

First Posted Date: 2021-11-05

Last Posted Date: 2024-01-22

Lead Sponsor: Ain Shams University

Target Recruit Count: 210

Registration Number: NCT05108688

Locations: 🇪🇬
Ain-Shams University Hospitals, Cairo, Egypt

Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine

Phase 4

Completed

Conditions: Agitation

Interventions: Drug: Melatonin
Drug: Placebo
Drug: Mirtazapine

First Posted Date: 2021-06-01

Last Posted Date: 2022-04-15

Lead Sponsor: Ain Shams University

Target Recruit Count: 165

Registration Number: NCT04908605

Locations: 🇪🇬
Ain-Shams University Hospitals, Cairo, Egypt

Role of Mirtazapine in Ameliorating Sleep Disordered Breathing

Phase 2

Completed

Conditions: Spinal Cord Injuries
Sleep Disordered Breathing

Interventions: Drug: Placebo
Drug: Mirtazapine

First Posted Date: 2021-03-16

Last Posted Date: 2021-06-15

Lead Sponsor: Wayne State University

Target Recruit Count: 18

Registration Number: NCT04799782

Mirtazapine in Cancer-related Poly-symptomatology

Phase 3

Terminated

Conditions: Cancer
Neoplasm Metastasis
Neoplasms

Interventions: Drug: Escitalopram
Drug: Mirtazapine

First Posted Date: 2021-02-21

Last Posted Date: 2023-06-08

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 1

Registration Number: NCT04763135

Locations: 🇫🇷
Hôpitaux universitaires de Strasbourg, Strasbourg, France
🇫🇷
Centre Hospitalier Lyon Sud, Pierre-Bénite, France
🇫🇷
Centre Hospitalier Universitaire de Clermont-Ferrand, Cébazat, France

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy